Niagen Bioscience, Inc. (NASDAQ:NAGE) Stock Now Rated “Buy” by Sell-Side Analysts

Niagen Bioscience, Inc. (NASDAQ:NAGE) has been assigned an average rating of “Buy” from the five analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $10.33.

A number of equities analysts have weighed in on NAGE shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, July 1st. Roth Capital reaffirmed a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. Finally, Freedom Capital raised shares of Niagen Bioscience to a “strong-buy” rating in a research report on Monday, July 6th.

Niagen Bioscience Stock Performance

NASDAQ:NAGE opened at $2.98 on Thursday. The stock has a fifty day moving average price of $3.15 and a two-hundred day moving average price of $3.71. The stock has a market capitalization of $237.33 million, a price-to-earnings ratio of 16.56 and a beta of 2.09. Niagen Bioscience has a 1 year low of $2.87 and a 1 year high of $10.06.

Niagen Bioscience (NASDAQ:NAGE) last posted its earnings results on Tuesday, August 4th. The company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $29.78 million for the quarter, compared to analyst estimates of $29.95 million. Niagen Bioscience had a return on equity of 17.95% and a net margin of 12.39%. On average, analysts predict that Niagen Bioscience will post 0.13 EPS for the current year.

Hedge Funds Weigh In On Niagen Bioscience

A number of institutional investors have recently added to or reduced their stakes in NAGE. Tidal Investments LLC bought a new position in Niagen Bioscience during the 2nd quarter valued at $394,000. Squarepoint Ops LLC increased its position in shares of Niagen Bioscience by 33.3% in the 2nd quarter. Squarepoint Ops LLC now owns 123,054 shares of the company’s stock worth $393,000 after purchasing an additional 30,711 shares during the last quarter. Tieton Capital Management LLC bought a new stake in shares of Niagen Bioscience in the 2nd quarter worth about $6,407,000. Bank of New York Mellon Corp acquired a new stake in shares of Niagen Bioscience in the 2nd quarter valued at about $647,000. Finally, Stoneridge Investment Partners LLC acquired a new stake in shares of Niagen Bioscience in the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a bioscience company focused on developing and commercializing products designed to support healthy aging and cellular energy metabolism. The company’s research centers on nicotinamide riboside (NR), a form of vitamin B3 and precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in numerous cellular processes.

The company markets its proprietary NIAGEN branded NR ingredient to supplement manufacturers and sells consumer products under the Tru Niagen brand.